Key terms

About CCCC

C4 Therapeutics, Inc. engages in the development of targeted protein degradation science to develop a new generation of small molecule medicines used for treating diseases. It develops the Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system. The company was founded by James E. Bradner, Kenneth C. Anderson, Nathanael S. Gray and Marc A. Cohen in October 2015 and is headquartered in Watertown, MA.

Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
     
52-week range
     
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date

Key terms

Smart score

Latest CCCC news

Apr 08 8:07am ET C4 Therapeutics presents new data for CFT1946 at AACR by TipRanks Mar 15 12:03pm ET JPMorgan biotech/pharma analysts hold an analyst/industry conference call by TipRanks Mar 08 4:23pm ET C4 Therapeutics Initiates Stock Option Repricing for Retention by TipRanks Mar 04 7:05am ET C4 Therapeutics announces research collaboration with Merck KGaA by TipRanks Feb 26 7:30am ET Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Halozyme (HALO) and Eli Lilly & Co (LLY) by TipRanks Feb 23 7:49am ET C4 Therapeutics price target raised to $13 from $12 at Stifel by TipRanks Feb 23 7:40am ET Strong Financials and Promising Drug Pipeline Bolster Buy Rating for C4 Therapeutics by TipRanks Feb 23 7:40am ET Analysts Offer Insights on Healthcare Companies: C4 Therapeutics (CCCC), Insulet (PODD) and Healthequity (HQY) by TipRanks Feb 23 7:33am ET C4 Therapeutics price target raised to $7 from $6 at Wells Fargo by TipRanks Feb 23 7:22am ET Stifel Nicolaus Sticks to Its Buy Rating for C4 Therapeutics (CCCC) by TipRanks Feb 23 6:01am ET Analysts Conflicted on These Healthcare Names: C4 Therapeutics (CCCC), Eli Lilly & Co (LLY) and Irhythm Technologies (IRTC) by TipRanks Feb 23 1:02am ET New Debt & Financing Risk for C4 Therapeutics, Inc. – What’s the Latest? by TipRanks Jan 12 8:26am ET C4 Therapeutics: Strategic Partnerships and Clinical Advancements Bolster Buy Rating by TipRanks Jan 10 11:45am ET C4 Therapeutics call volume above normal and directionally bullish by TipRanks

No recent press releases are available for CCCC

CCCC Financials

1-year income & revenue

Key terms

CCCC Forecasts

analyst rating

  • buy
  • hold
  • sell

We're sorry, but this
information is
temporarily unavailable.

1-year stock price forecast

CCCC Competitors

$ Market cap P/E ratio $ Price 1d change 52-week range

Key terms

Latest investing news

People walk past the New York Stock Exchange Thursday, March. 21, 2024.
Yuki Iwamura/AP
Investors are fearful. They shouldn’t be
People walk past the New York Stock Exchange (NYSE) on March 28, 2024 in New York City.
NDZ/STAR MAX/IPx/AP
What stalled this year’s seemingly infallible stock market rally
A working oil pumpjack is pictured in Taft, Kern County, California on September 21, 2023.
Frederic J. Brown/AFP/Getty Images
Oil prices get short-lived boost from attack on Iran
NEW YORK, NEW YORK - FEBRUARY 08: A New York Community Bank stands in Brooklyn on February 08, 2024 in New York City. New York Community Bancorp, a regional lender, shed about 60% of its value over the past eight days and its credit rating has been downgraded to Junk by Moody's. (Photo by Spencer Platt/Getty Images)
Spencer Platt/Getty Images
US regional banks are still under pressure. That’s likely to continue